Domain > dlbcl-information.com

More information on this domain is in AlienVault OTX

DNS Resolutions

Date	IP Address
2025-03-23	20.49.104.33 (ClassC)

Port 443

HTTP/1.1 200 OKContent-Type: text/html; charsetutf-8Date: Sun, 04 Aug 2024 11:31:54 GMTServer: nginx/1.26.1Transfer-Encoding: chunkedX-Powered-By: PHP/8.2.20

!DOCTYPE html>html langen>head>  !-- OneTrust Cookies Consent Notice start -->  !-- script srchttps://cdn.cookielaw.org/consent/018f29dd-3720-77c5-9694-7937b26c6901/otSDKStub.js  typetext/javascript charsetUTF-8 data-domain-script018f29dd-3720-77c5-9694-7937b26c6901 >/script> -->  script srchttps://cdn.cookielaw.org/consent/a364a716-5af3-47c5-85bc-66ef2cf68a77/otSDKStub.js  typetext/javascript charsetUTF-8 data-domain-scripta364a716-5af3-47c5-85bc-66ef2cf68a77 >/script>          script typeapplication/ld+json>      {        @context: https://schema.org/,        @type: MedicalWebPage,        url: https://www.monjuvi.com,        audience: https://health-lifesci.schema.org/Patient,        creator: {            @type: Organization,            name: MorphoSys US Inc.,            url: https://www.morphosys-us.com,            logo: https://www.monjuvi.com/images/morphosys-logo.png,            sameAs: https://en.wikipedia.org/wiki/MorphoSys          },        mainEntity: {          @type: Drug,          name: MONJUVI,          sameAs: https://en.wikipedia.org/wiki/Tafasitamab,          image: https://www.monjuvi.com/images/monjuvi-logo.png,          activeIngredient: tafasitamab-cxix,          nonProprietaryName: tafasitamab-cxix,          legalStatus: FDA Approved,          isProprietary: True,          isAvailableGenerically: False,          relevantSpecialty: https://health-lifesci.schema.org/Oncologic,          manufacturer: {            @type: Organization,            name: MorphoSys US Inc.,            url: https://www.morphosys-us.com,            logo: https://www.monjuvi.com/images/morphosys-logo.png,            sameAs: https://en.wikipedia.org/wiki/MorphoSys          },          description: MONJUVI is an FDA-approved medicine for adults who have diffuse large B-cell lymphoma, or DLBCL that has progressed after at least one prior therapy and who are not eligible for stem cell transplant. MONJUVI is given with lenalidomide, another cancer medicine. Together, these medicines are used to treat people whose disease

View on OTX | View on ThreatMiner

Data with thanks to AlienVault OTX, VirusTotal, Malwr and others. [Sitemap]

Domain > dlbcl-information.com

Is this malicious?

DNS Resolutions

Port 443